Form 4: Trulieve Director Thomas Millner Acquires 8,000 Shares
SEC Form 4
Trulieve Cannabis Corp. director Thomas Millner purchased 8,000 subordinate voting shares at $6.12 each on November 19, 2024.
Summary
- Thomas Millner, a director at Trulieve Cannabis Corp., acquired 8,000 subordinate voting shares.
- The transaction occurred on November 19, 2024.
- The shares were purchased at a price of $6.12 per share.
- Following the transaction, Mr. Millner directly owns 30,495 subordinate voting shares.
Sentiment
Score: 5
Explanation: The document is a neutral disclosure of a director's share purchase, with no inherent positive or negative sentiment.
Positives
- The purchase by a director may signal confidence in the company's future prospects.
Industry Context
This is a routine disclosure of insider trading activity, which is common in publicly traded companies. It does not indicate any specific trend in the cannabis industry.
Comparison to Industry Standards
- Insider trading disclosures are a standard practice for all publicly listed companies, including those in the cannabis sector.
- The transaction is relatively small in scale compared to large institutional trades, but is typical for individual director purchases.
Stakeholder Impact
- The transaction may have a minor positive impact on shareholder sentiment due to the director's purchase.
Key Dates
| Date | Description |
|---|---|
| 11/19/2024 | Date of the share purchase transaction. |
| 11/21/2024 | Date the form was signed by Eric Powers, as Attorney-in-Fact. |
Keywords
Trulieve, Cannabis, Director, Share Purchase, Insider Trading, Subordinate Voting Shares, Thomas Millner
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.